Multicentre, randomised, double-blinded, active-controlled, cross-over phase 3 trial on safety and efficacy of rFVIIa analogue (vatreptacog alfa) in haemophilia patients with inhibitors (adept (TM)(2))

MLA

Lentz, S. R., et al. Multicentre, Randomised, Double-Blinded, Active-Controlled, Cross-over Phase 3 Trial on Safety and Efficacy of RFVIIa Analogue (Vatreptacog Alfa) in Haemophilia Patients with Inhibitors (Adept (TM)(2)). EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..4ed6a33d113a226aa12ea050f17cea2b&authtype=sso&custid=ns315887. Accessed 27 Feb. 2025.

APA

Lentz, S. R., Mahlangu, J., Karim, A. F. A., Andreeva, T., Economou, M., Ehrenforth, S., & Jerzy Windyga. (n.d.). Multicentre, randomised, double-blinded, active-controlled, cross-over phase 3 trial on safety and efficacy of rFVIIa analogue (vatreptacog alfa) in haemophilia patients with inhibitors (adept (TM)(2)).

Chicago

Lentz, S. R., J. Mahlangu, Abdul F. A. Karim, T. Andreeva, M. Economou, S. Ehrenforth, and Jerzy Windyga. 2025. “Multicentre, Randomised, Double-Blinded, Active-Controlled, Cross-over Phase 3 Trial on Safety and Efficacy of RFVIIa Analogue (Vatreptacog Alfa) in Haemophilia Patients with Inhibitors (Adept (TM)(2)).” Accessed February 27. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..4ed6a33d113a226aa12ea050f17cea2b&authtype=sso&custid=ns315887.